Dr. Bodkin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5555 Grossmont Center Dr
La Mesa, CA 91942Phone+1 619-644-3030Fax+1 619-644-3438
Education & Training
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1984 - 1987
Georgetown University School of MedicineClass of 1984
Certifications & Licensure
CA State Medical License 1988 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014
- Top MD Consumers Checkbook
Clinical Trials
- Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin Start of enrollment: 2011 Jan 16
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Publications & Presentations
PubMed
- 156 citationsRandomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–S...Charles A. Butts, David Bodkin, Edward L. Middleman, Craig W. Englund, David W. Ellison
Journal of Clinical Oncology. 2007-12-20 - 14 citationsSimultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform.Juan Pablo Hinestrosa, David Searson, Jean M. Lewis, Alfred Kinana, Orlando Perrera
Frontiers in Bioengineering and Biotechnology. 2020-11-05 - 183 citationsVandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II StudyRonald B. Natale, David Bodkin, Ramaswamy Govindan, Bethany G. Sleckman, Naiyer A. Rizvi
Journal of Clinical Oncology. 2009-05-20
Press Mentions
Haims: Prevalence of Colon Cancer in People Under 50 Is AlarmingApril 24th, 2023
New Breast Cancer Gene Puts Younger Women at RiskMay 8th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
